Artesunate for Injection 210 mg — Dry Powder Injections
WHO-GMP Certified Commercial Pack · Product Code: AKP-010-MAL

Artesunate for Injection 210 mg

Formulation Overview: WHO first-line parenteral artemisinin-derivative sterile vial (210 mg artesunate with co-packed sodium bicarbonate activator & saline diluent) engineered for life-saving IV/IM emergency malaria treatment across endemic regions. Formulated with Artesunate 210 mg (210 mg) in Sterile Dry Powder Injection Vial + Co-packed Diluent dosage form under Antimalarials Medication, manufactured to IP / BP / USP Compendial standards and supplied in 1 Vial + Diluent USP Type I Glass Vial (with WFI & Bicarbonate Diluent) with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
Item Code (SKU)AKP-010-MAL
Catalog ReferenceAKP-010 · SN 10
Therapeutic SectorAntimalarials Medication
Dosage FormSterile Dry Powder Injection Vial + Co-packed Diluent
Active IngredientArtesunate 210 mg
Strength / Purity210 mg
Clinical IndicationSevere and cerebral Plasmodium falciparum malaria requiring rapid parenteral parasitemia clearance
Specification StandardIP / BP / USP Compendial
Packaging Format1 Vial + Diluent USP Type I Glass Vial (with WFI & Bicarbonate Diluent)
Shelf Life24–36 Months
Storage ConditionsStore below 25°C, protect from light & freezing; use immediately upon reconstitution
Minimum Order Quantity1000 Packs
Regulatory / Analytical DocsFull eCTD / ACTD Modules 1–5 + Zone IVb Stability Available
African & Global NRA ReadinessNAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA
Stock AvailabilityIn Stock · Immediate Commercial Dispatch
Supply StatusCommercial Export Ready

Related Dry Powder Injections & Antimalarials Medication